|
|
|
| Detection of autoantibodies in the serum of primary hepatocarcinoma patients |
| Fang Fang, Hua-Liang Wang, Ping Ye, Hai-Lin Deng, Gui-Ling Dong, Li-Ling Ma and Jian Wang |
From the Department of Clinical Laboratory, Shanghai Eastern Hepatobiliary Hospital, Shanghai 200418, China (Fang F, Wang HL, Ye P, Deng HL, Dong GL, Ma LL and Wang J)
Correspondence: Fang Fang, MD (Tel: 86-21-25070849; Fax: 86-21-25070850) |
|
|
|
|
Abstract Objective: To study the significance of detecting autoantibodies in primary hepatocarcinoma (PHC) patients.
Methods: Autoantibodies were detected by indirect immunofluorescence assay. Antigens and antibodies of HBV were determined by enzyme immune assay. Antibody to HCV IgG was detected by enzyme-linked immunoabsorbent assay.
Results: The positive rate of autoantibody was 27.3% (38/139) in 139 PHC patients. The main type of autoantibodies in PHC was anti-nuclear antibody (36/38, 94.7%), others included anti-smooth muscle antibody(2/38, 5.3%), anti-mitochondria antibody (1/38, 2.6%), anti-midbody antibody (1/38, 2.6%, and anti-liver cell membrane antibody (2/38, 5.3%).
Conclusions: Detecting autoantibodies in PHC patients is of significance in studying the mechanism of autoimmune reaction and etiology in PHC. The diversity of autoantibodies might result from a wide variety of etiological factors involved in PHC development, and from a wide variety of overexpressed or mutated proteins involved in repeated cycles of necrosis and regeneration in hepatocarcinoma development.
|
|
|
|
|
|
|
|
|
2002, Vol. 1 
